Novel Insights into Breast Cancer Genetic Variance through RNA Sequencing

Size: px
Start display at page:

Download "Novel Insights into Breast Cancer Genetic Variance through RNA Sequencing"

Transcription

1 Insights into Breast Cancer Genetic Variance through RNA Sequencing SUPPLEMENTARY DATA Anelia Horvath, 1,2* Suresh Babu Pakala, 2* Prakriti Mudvari, 1* Sirigiri Divijendra Natha Reddy, 2 Kazufumi Ohshiro, 2 Sandra Casimiro, 3 Ricardo Pires, 3 Suzanne A. W. Fuqua 4, Masakazu Toi, 5 Luis Costa, 3 Sujit Nair, 2 Saraswati Sukumar, 6 & Rakesh Kumar 1,2# 1 McCormick Genomic and Proteomics Center, 2 Department of Biochemistry and Molecular Medicine, The George Washington University, Washington, District of Columbia 20037, USA; 3 Institute of Molecular Medicine and, Hospital de Santa Maria CHLN, Lisbon, Portugal; 4 Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA; 5 Department of of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan; 6 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA *Equal contribution #Correspondence: bcmrxk@gwu.edu 1 Manuscript Information Figures: 5 Tables: 4 Supplementary Information Figures: 1 Tables: 4

2 Supplementary Figure 1. Top affected molecular networks were cell death and survival, cellular development, and cellular growth and proliferation, and the top affected canonical pathway was estrogen receptor signaling

3 Supplementary Table 1. SNPs and INDELs identified across 17 Breast Cancer Samples. Sample Variant Total (prior to filtering) (prior to filtering) Known + Filtered Known + Filtered (genic) Known + Filtered (Exonic) TNBC Non-TNBC HER-2 Positive Summary SUM AVE UNIQUE SNPs Genes Indels Genes SNP Genes Indels Genes SNPs Genes Indels Genes SNPs Genes Indels Genes SNPs Genes Indels Genes

4 Supplementary Table 2. Overlap between the variations found by our study and the publically available genome wide association studies (GWAS) genelist #rsid Sample QUAL INFO accepted_hits.baccession functiongvsscorephastcconsscoregeafr EUR AS genomesesp none rs DP=2;VDB=0.0156;AF1=1;AC1=2;DP4=0,0,2,0;MQ=20;FQ=-33 1/1:32,6,0:4 none intergenic unknown PBX1 rs DP=8;VDB=0.0300;AF1=1;AC1=2;DP4=0,1,5,2;MQ=20;FQ=-31;PV4=0.37,0.0014,1,1 1/1:86,4,0:7 NM_ intron unknown PBX1 rs DP=8;VDB=0.0453;AF1=0.4999;AC1=1;DP4=3,1,2,1;MQ=20;FQ=9.38;PV4=1,0.0005,1,1 0/1:36,0,50:37 NM_ intron unknown PBX1 rs DP=14;VDB=0.0453;AF1=0.5;AC1=1;DP4=4,3,4,1;MQ=20;FQ=22;PV4=0.58,0.0057,1,1 0/1:49,0,77:52 NM_ intron unknown PBX1 rs DP=6;VDB=0.0640;AF1=1;AC1=2;DP4=0,0,2,4;MQ=20;FQ=-45 1/1:90,18,0:33 NM_ intron unknown RNF146 rs DP=8;VDB=0.0527;AF1=1;AC1=2;DP4=0,0,2,6;MQ=20;FQ=-51 1/1:116,24,0:45 NM_ intron unknown RNF146 rs DP=2;VDB=0.0673;AF1=1;AC1=2;DP4=0,0,1,1;MQ=20;FQ=-33 1/1:40,6,0:8 NM_ intron unknown RNF146 rs DP=5;VDB=0.0673;AF1=1;AC1=2;DP4=0,0,3,2;MQ=20;FQ=-42 1/1:85,15,0:27 NM_ intron unknown RNF146 rs DP=2;VDB=0.0640;AF1=1;AC1=2;DP4=0,0,2,0;MQ=20;FQ=-33 1/1:36,6,0:6 NM_ intron unknown FGFR2 rs DP=4;VDB=0.0453;AF1=1;AC1=2;DP4=0,0,2,2;MQ=20;FQ=-39 1/1:73,12,0:21 NM_ intron unknown FGFR2 rs DP=9;VDB=0.0591;AF1=1;AC1=2;DP4=0,0,6,3;MQ=20;FQ=-54 1/1:123,27,0:51 NM_ intron unknown FGFR2 rs DP=4;VDB=0.0668;AF1=1;AC1=2;DP4=0,0,2,1;MQ=20;FQ=-36 1/1:56,9,0:15 NM_ intron unknown FGFR2 rs DP=5;VDB=0.0661;AF1=1;AC1=2;DP4=0,0,3,2;MQ=20;FQ=-42 1/1:85,15,0:27 NM_ intron unknown LSP1 rs DP=2;VDB=0.0527;AF1=1;AC1=2;DP4=0,0,1,1;MQ=20;FQ=-33 1/1:40,6,0:8 NM_ intron unknown LSP1 rs DP=2;VDB=0.0591;AF1=1;AC1=2;DP4=0,0,1,1;MQ=20;FQ=-33 1/1:40,6,0:8 NM_ intron unknown none rs DP=12;VDB=0.0300;AF1=1;AC1=2;DP4=0,1,4,5;MQ=20;FQ=-37;PV4=1,7.7e-07,1,0.3 1/1:114,10,0:17 none intergenic unknown none rs DP=6;VDB=0.0232;AF1=1;AC1=2;DP4=0,0,2,4;MQ=20;FQ=-45 1/1:98,18,0:33 none intergenic unknown none rs DP=2;VDB=0.0167;AF1=1;AC1=2;DP4=0,0,0,2;MQ=20;FQ=-33 1/1:36,6,0:6 none intergenic unknown none rs DP=4;VDB=0.0029;AF1=0.543;AC1=1;DP4=1,0,1,2;MQ=20;FQ=-19;PV4=1,0.013,1,1 0/1:45,0,8:11 none intergenic unknown ZMIZ1 rs DP=2;VDB=0.0233;AF1=1;AC1=2;DP4=0,0,2,0;MQ=20;FQ=-33 1/1:36,6,0:6 NM_ intron unknown ZMIZ1 rs DP=4;VDB=0.0542;AF1=1;AC1=2;DP4=0,0,2,1;MQ=20;FQ=-36 1/1:56,9,0:15 NM_ intron unknown BABAM1 rs DP=34;VDB=0.0673;AF1=1;AC1=2;DP4=3,2,26,3;MQ=20;FQ=-35;PV4=0.15,0.0003,1,0.19 1/1:78,8,0:14 NM_ coding-syno A=2226/G=10096 BABAM1 rs DP=30;VDB=0.0673;AF1=1;AC1=2;DP4=0,0,21,7;MQ=20;FQ=-111 1/1:167,84,0:99 NM_ coding-syno A=2226/G=10096 BABAM1 rs DP=22;VDB=0.0376;AF1=0.5;AC1=1;DP4=10,2,8,2;MQ=20;FQ=48.5;PV4=1, ,1, /1:76,0,85:78 NM_ coding-syno A=2226/G=10096 SLC4A7 rs DP=19;VDB=0.0591;AF1=1;AC1=2;DP4=1,1,5,12;MQ=20;FQ=-44;PV4=1,1.2e-07,1,1 1/1:128,17,0:31 NM_ utr unknown SLC4A7 rs DP=6;VDB=0.0527;AF1=1;AC1=2;DP4=0,0,3,3;MQ=20;FQ=-45 1/1:98,18,0:33 NM_ utr SLC4A7 rs DP=7;VDB=0.0368;AF1=0.4998;AC1=1;DP4=2,2,2,1;MQ=20;FQ=5.45;PV4=1, ,1,0.2 0/1:31,0,53:30 NM_ utr unknown SLC4A7 rs DP=13;VDB=0.0640;AF1=1;AC1=2;DP4=0,1,7,3;MQ=20;FQ=-40;PV4=0.36,9.7e-07,1,1 1/1:111,13,0:23 NM_ utr unknown SLC4A7 rs DP=9;VDB=0.0376;AF1=0.5003;AC1=1;DP4=2,1,4,2;MQ=20;FQ=4.77;PV4=1, ,1,0.34 0/1:68,0,30:33 NM_ utr unknown SLC4A7 rs DP=4;VDB=0.0268;AF1=1;AC1=2;DP4=0,0,3,1;MQ=20;FQ=-39 1/1:64,12,0:21 NM_ utr

5 Supplementary Table 3. Number of novel SNPs and INDELs after filtering; the within gene located variants and protein altering variant numbers are also shown, together with the affected genes number Samples TNBC Non-TNBC HER-2 Positive Summary Variants SUM AVE UNIQ (Total) SNPs Indels SNPs (Within Genes) Genes Indels Genes Total* Nonsense Missense (Exonic) Splice Site Genes Indels Genes *Total number SNPs includes synonymous

6 Supplementary Table 4. variants showing allele preferential expression Gene Sample Subtype CHR POS REF ALT QUAL Function GVS AA PROT PPH CONS Phas Cons GERP# Ref reads # Var reads AGRN 78 TNBC G A 131 coding-synonymous none 1517/2046unknown AP2A1 83 TNBC 19 5E+07 G T,A 25.1 splice-3 none NA unknown ARHGAP18 90 TNBC 6 1.3E+08 C T 78.1 missense ALA,THR 382/ ATM 66 Non-TNBC E+08 T G 98 splice-5 none NA unknown BRK1 48 Non-TNBC 3 1E+07 A G 27.3 splice-3 none NA unknown BTBD18 26 HER E+07 C T 116 missense GLU,LYS 564/ CACNA1C 66 Non-TNBC T C 89.4 splice-5 none NA unknown CASC3 56 HER E+07 G A 53.1 missense ALA,THR 670/ CASP3 26 HER E+08 A T 90.2 splice-5 none NA unknown CD44 42 Non-TNBC E+07 A C 24.2 splice-3 none NA unknown CHD3 48 Non-TNBC G T 89.4 coding-synonymous none 1463/1967unknown CHD4 69 TNBC C T 89.1 splice-5 none NA unknown CHGB 66 Non-TNBC G C 28.5 splice-5 none NA unknown COL16A1 49 Non-TNBC 1 3.2E+07 A T,C 26.5 splice-5 none NA unknown CP 42 Non-TNBC 3 1.5E+08 C G 49.5 splice-5 none NA unknown CYC1 26 HER E+08 T G 127 coding-synonymous none 207/326 unknown DBI 83 TNBC 2 1.2E+08 T G 28.1 splice-5 none NA unknown DDX52 56 HER E+07 T A 87.2 missense ILE,PHE 463/ DHX8 76 TNBC E+07 G A 45.5 coding-synonymous none 902/1221 unknown DIP2A 78 TNBC E+07 T A 40.2 missense SER,THR 1096/ DPM1 69 TNBC 20 5E+07 A T 101 splice-5 none NA unknown DRAP1 48 Non-TNBC E+07 A C 66.1 splice-3 none NA unknown DSG1 26 HER E+07 G A 53.1 missense VAL,ILE 808/ EFCAB4A 49 Non-TNBC G C 78.1 missense ARG,PRO 193/ EIF3H 48 Non-TNBC 8 1.2E+08 C G 113 coding-synonymous none 173/353 unknown ENO1 42 Non-TNBC G A 124 coding-synonymous none 123/435 unknown EXOC2 42 Non-TNBC A G 86 coding-synonymous none 567/925 unknown FASN 53 HER2 17 8E+07 G A 93.8 coding-synonymous none 294/2512 unknown FBN1 65 Non-TNBC E+07 T A 28.5 splice-3 none NA unknown FBXO21 42 Non-TNBC E+08 A C 52.1 splice-5 none NA unknown FLNB 42 Non-TNBC 3 5.8E+07 A C 56.1 splice-3 none NA unknown GOLGA4 78 TNBC 3 3.7E+07 G A 130 missense VAL,ILE 887/ HCFC2 90 TNBC 12 1E+08 G C 40.1 missense LYS,ASN 787/ HDAC1 42 Non-TNBC 1 3.3E+07 T G 42.3 splice-5 none NA unknown HDDC2 42 Non-TNBC 6 1.3E+08 G C 112 missense LEU,VAL 117/ HDLBP 90 TNBC 2 2.4E+08 G A 156 coding-synonymous none 1018/1269unknown IBTK 49 Non-TNBC 6 8.3E+07 C T 64 splice-5 none NA unknown ILF3 42 Non-TNBC E+07 T G 25.2 splice-5 none NA unknown INPP4A 83 TNBC 2 9.9E+07 A G 53.1 splice-3 none NA unknown ITPR1 71 Non-TNBC T C 55.5 coding-synonymous none 117/2696 unknown KDM2A 78 TNBC E+07 T G 132 splice-5 none NA unknown LMF2 90 TNBC E+07 G A 59.5 missense PRO,LEU 632/ LOC Non-TNBC E+07 T C 118 coding-synonymous none 70/190 unknown LOC Non-TNBC E+07 T A 77 coding-synonymous none 91/190 unknown LOC Non-TNBC E+07 C G 45.5 missense GLN,HIS 97/190 unknown LRRC42 42 Non-TNBC 1 5.4E+07 G A 25.5 splice-5 none NA unknown LYZ 42 Non-TNBC 12 7E+07 T G 29.1 splice-5 none NA unknown MAGED1 90 TNBC X 5.2E+07 G C 105 missense GLY,ALA 87/ MARS 26 HER E+07 C T 129 missense THR,ILE 217/ MCM6 49 Non-TNBC 2 1.4E+08 A T,C 42.1 splice-5 none NA unknown MCTS1 48 Non-TNBC X 1.2E+08 G T 72.5 splice-3 none NA unknown MLH1 76 TNBC 3 3.7E+07 A T 60.1 splice-3 none NA unknown MTAP 53 HER E+07 A G 47.1 missense LYS,ARG 71/ MTIF2 26 HER E+07 G A 113 missense HIS,TYR 678/ MYO1B 76 TNBC 2 1.9E+08 G A 90 coding-synonymous none 210/1079 unknown

7 Supplementary Table 4 (cont). variants showing allele preferential expression Gene Sample Subtype CHR POS REF ALT QUAL Function GVS AA PROT PPH CONS Phas Cons GERP# Ref reads # Var reads MYOF 56 HER E+07 A G 109 splice-5 none NA unknown MYT1 90 TNBC E+07 T A 31.5 coding-synonymous none 836/1122 unknown NCAPD3 26 HER E+08 A C 137 missense LEU,TRP 1087/ NOP58 78 TNBC 2 2E+08 G A 38.2 splice-5 none NA unknown NOTCH3 48 Non-TNBC E+07 T C 25.5 splice-3 none NA unknown NR2F6 50 TNBC E+07 G A 148 coding-synonymous none 170/405 unknown NR3C1 42 Non-TNBC 5 1.4E+08 A G 19.2 splice-5 none NA unknown PFKL 83 TNBC E+07 C T 116 coding-synonymous none 532/781 unknown PKM 42 Non-TNBC E+07 G C 106 missense PRO,ALA 477/ PKN2 50 TNBC 1 8.9E+07 A G 31.5 splice-3 none NA unknown PLOD1 78 TNBC 1 1.2E+07 G A 25.3 splice-5 none NA unknown PPA1 42 Non-TNBC E+07 C T 67.1 splice-5 none NA unknown PPP2CB 83 HER E+07 C T 60.1 splice-5 none NA unknown PPP4C 42 Non-TNBC 16 3E+07 G C 36.1 splice-5 none NA unknown PRKDC 26 HER E+07 C T 36.5 splice-3 none NA unknown PTPRA 56 HER G T 78.1 splice-3 none NA unknown PTPRS 26 HER A G 89.4 splice-5 none NA unknown RBBP4 53 HER E+07 G A 66.1 coding-synonymous none 26/426 unknown RDX 42 Non-TNBC E+08 A T,G 103 splice-5 none NA unknown RFC4 83 TNBC 3 1.9E+08 T A 46.3 splice-3 none NA unknown RGPD3 53 HER E+08 A G 84 missense-near-splice MET,THR 586/ RNF40 42 Non-TNBC E+07 G C 46.3 splice-5 none NA unknown RNF41 26 HER E+07 C T 146 coding-synonymous-nenone 166/318 unknown RRP7A 42 Non-TNBC E+07 A T 34.2 splice-5 none NA unknown SCNN1A 42 Non-TNBC G A 62.1 coding-synonymous none 483/729 unknown SERPINA3 69 TNBC E+07 T A 222 missense SER,THR 302/ SHARPIN 42 Non-TNBC 8 1.5E+08 C T 119 coding-synonymous-nenone 67/388 unknown SIPA1L2 78 TNBC 1 2.3E+08 C T 94 splice-5 none NA unknown SPHK1 26 HER E+07 C T 74.1 missense ARG,CYS 365/ SPTBN1 53 HER E+07 T C 82.1 coding-synonymous none 1547/2156unknown ST6GALNAC83 HER E+08 G A 40.2 missense ARG,CYS 198/ STRN3 42 Non-TNBC E+07 C T 57 splice-5 none NA unknown SUN2 26 HER E+07 C T 89.4 coding-synonymous none 718/718 unknown SYTL4 49 Non-TNBC X 1E+08 A T 106 splice-5 none NA unknown TFDP2 66 Non-TNBC 3 1.4E+08 C T 48.1 splice-5 none NA unknown TMEM Non-TNBC 2 2E+08 A C 73 splice-5 none NA unknown TNS3 83 HER E+07 C T 30.2 splice-5 none NA unknown TRAP1 26 HER G A 58.5 missense THR,ILE 328/ TRAPPC9 26 HER E+08 G A 128 coding-synonymous none 255/1247 unknown TRIM2 90 TNBC 4 1.5E+08 C G 126 missense SER,CYS 522/ TRIP12 66 Non-TNBC 2 2.3E+08 T A 30.5 splice-3 none NA unknown TSPAN5 78 TNBC 4 9.9E+07 A T 97 splice-5 none NA unknown TTBK2 26 HER E+07 A T 24.8 splice-5 none NA unknown UTP20 42 Non-TNBC 12 1E+08 A T 21.3 splice-3 none NA unknown VTI1B 42 Non-TNBC E+07 A C 66.1 splice-5 none NA unknown WARS 50 TNBC 14 1E+08 A C 46.3 splice-5 none NA unknown WDR47 49 Non-TNBC 1 1.1E+08 A G 34.2 splice-5 none NA unknown XYLT1 171 HER E+07 G A 66.1 missense SER,LEU 450/ YIF1B 69 TNBC E+07 G T 66.1 missense ASP,GLU 104/ ZC3H HER E+07 C T 115 splice-5 none NA unknown ZC3H15 42 Non-TNBC 2 1.9E+08 G A 50.1 splice-5 none NA unknown ZFYVE HER E+07 A G 53.1 splice-5 none NA unknown ZRANB2 66 Non-TNBC 1 7.2E+07 C T 122 splice-5 none NA unknown

RNA sequencing of cancer reveals novel splicing alterations

RNA sequencing of cancer reveals novel splicing alterations RNA sequencing of cancer reveals novel splicing alterations Jeyanthy Eswaran, Anelia Horvath, Sucheta Godbole, Sirigiri Divijendra Reddy, Prakriti Mudvari, Kazufumi Ohshiro, Dinesh Cyanam, Sujit Nair,

More information

Supplementary Table 1. Information on the 174 single nucleotide variants identified by whole-exome sequencing

Supplementary Table 1. Information on the 174 single nucleotide variants identified by whole-exome sequencing Supplementary Table 1. Information on the 174 single nucleotide s identified by whole-exome sequencing Chr Position Type AF exomes Database 1 10163148 A/G UBE4B missense 0.000326 1534 2 98 1 4.44 Damaging

More information

BWA alignment to reference transcriptome and genome. Convert transcriptome mappings back to genome space

BWA alignment to reference transcriptome and genome. Convert transcriptome mappings back to genome space Whole genome sequencing Whole exome sequencing BWA alignment to reference transcriptome and genome Convert transcriptome mappings back to genome space genomes Filter on MQ, distance, Cigar string Annotate

More information

CHR POS REF OBS ALLELE BUILD CLINICAL_SIGNIFICANCE

CHR POS REF OBS ALLELE BUILD CLINICAL_SIGNIFICANCE CHR POS REF OBS ALLELE BUILD CLINICAL_SIGNIFICANCE is_clinical dbsnp MITO GENE chr1 13273 G C heterozygous - - -. - DDX11L1 chr1 949654 A G Homozygous 52 - - rs8997 - ISG15 chr1 1021346 A G heterozygous

More information

Supplementary Figure 1. Quantile-quantile (Q-Q) plot of the log 10 p-value association results from logistic regression models for prostate cancer

Supplementary Figure 1. Quantile-quantile (Q-Q) plot of the log 10 p-value association results from logistic regression models for prostate cancer Supplementary Figure 1. Quantile-quantile (Q-Q) plot of the log 10 p-value association results from logistic regression models for prostate cancer risk in stage 1 (red) and after removing any SNPs within

More information

Supplementary Figure 1

Supplementary Figure 1 Count Count Supplementary Figure 1 Coverage per amplicon for error-corrected sequencing experiments. Errorcorrected consensus sequence (ECCS) coverage was calculated for each of the 568 amplicons in the

More information

Nature Neuroscience: doi: /nn Supplementary Figure 1. Missense damaging predictions as a function of allele frequency

Nature Neuroscience: doi: /nn Supplementary Figure 1. Missense damaging predictions as a function of allele frequency Supplementary Figure 1 Missense damaging predictions as a function of allele frequency Percentage of missense variants classified as damaging by eight different classifiers and a classifier consisting

More information

Clinical Genetics. Functional validation in a diagnostic context. Robert Hofstra. Leading the way in genetic issues

Clinical Genetics. Functional validation in a diagnostic context. Robert Hofstra. Leading the way in genetic issues Clinical Genetics Leading the way in genetic issues Functional validation in a diagnostic context Robert Hofstra Clinical Genetics Leading the way in genetic issues Future application of exome sequencing

More information

SUPPLEMENTARY INFORMATION. Meta-analyses of genome-wide association studies identify multiple novel loci related to pulmonary function

SUPPLEMENTARY INFORMATION. Meta-analyses of genome-wide association studies identify multiple novel loci related to pulmonary function SUPPLEMENTARY INFORMATION Meta-analyses of genome-wide association studies identify multiple novel loci related to pulmonary function Dana B. Hancock, 1,29 Mark Eijgelsheim, 2,29 Jemma B. Wilk, 3,29 Sina

More information

TP53 mutational profile in CLL : A retrospective study of the FILO group.

TP53 mutational profile in CLL : A retrospective study of the FILO group. TP53 mutational profile in CLL : A retrospective study of the FILO group. Fanny Baran-Marszak Hopital Avicenne Bobigny France 2nd ERIC workshop on TP53 analysis in CLL, Stresa 2017 TP53 abnormalities :

More information

Genome-wide association analyses identify 13 new susceptibility loci for generalized

Genome-wide association analyses identify 13 new susceptibility loci for generalized Supplementary information for: Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo Ying Jin 1,2, Stanca A Birlea 1,3, Pamela R Fain 1,2,4, Tracey M Ferrara 1,

More information

indicated in shaded lowercase letters (hg19, Chr2: 217,955, ,957,266).

indicated in shaded lowercase letters (hg19, Chr2: 217,955, ,957,266). Legend for Supplementary Figures Figure S1: Sequence of 2q35 encnv. The DNA sequence of the 1,375bp 2q35 encnv is indicated in shaded lowercase letters (hg19, Chr2: 217,955,892-217,957,266). Figure S2:

More information

Downloaded for Anonymous User (n/a) at University of Washington - Seattle - WSC from ClinicalKey.com by Elsevier on March 04, 2019.

Downloaded for Anonymous User (n/a) at University of Washington - Seattle - WSC from ClinicalKey.com by Elsevier on March 04, 2019. Accepted Manuscript The MALT1 locus and Peanut Avoidance in the Risk for Peanut Allergy Alexandra Winters, PhD, Henry T. Bahnson, MPH, Ingo Ruczinski, PhD, Meher P. Boorgula, MS, Claire Malley, MS, Ali

More information

Concurrent Practical Session ACMG Classification

Concurrent Practical Session ACMG Classification Variant Effect Prediction Training Course 6-8 November 2017 Prague, Czech Republic Concurrent Practical Session ACMG Classification Andreas Laner / Anna Benet-Pagès 1 Content 1. Background... 3 2. Aim

More information

TITLE: - Whole Genome Sequencing of High-Risk Families to Identify New Mutational Mechanisms of Breast Cancer Predisposition

TITLE: - Whole Genome Sequencing of High-Risk Families to Identify New Mutational Mechanisms of Breast Cancer Predisposition AD Award Number: W81XWH-13-1-0336 TITLE: - Whole Genome Sequencing of High-Risk Families to Identify New Mutational Mechanisms of Breast Cancer Predisposition PRINCIPAL INVESTIGATOR: Mary-Claire King,

More information

6/12/2018. Disclosures. Clinical Genomics The CLIA Lab Perspective. Outline. COH HopeSeq Heme Panels

6/12/2018. Disclosures. Clinical Genomics The CLIA Lab Perspective. Outline. COH HopeSeq Heme Panels Clinical Genomics The CLIA Lab Perspective Disclosures Raju K. Pillai, M.D. Hematopathologist / Molecular Pathologist Director, Pathology Bioinformatics City of Hope National Medical Center, Duarte, CA

More information

Investigating causality in the association between 25(OH)D and schizophrenia

Investigating causality in the association between 25(OH)D and schizophrenia Investigating causality in the association between 25(OH)D and schizophrenia Amy E. Taylor PhD 1,2,3, Stephen Burgess PhD 1,4, Jennifer J. Ware PhD 1,2,5, Suzanne H. Gage PhD 1,2,3, SUNLIGHT consortium,

More information

Accel-Amplicon Panels

Accel-Amplicon Panels Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation

More information

A genome-wide association study identifies vitiligo

A genome-wide association study identifies vitiligo A genome-wide association study identifies vitiligo susceptibility loci at MHC and 6q27 Supplementary Materials Index Supplementary Figure 1 The principal components analysis (PCA) of 2,546 GWAS samples

More information

Supplementary information: Forstner, Hofmann et al.

Supplementary information: Forstner, Hofmann et al. Supplementary information: Forstner, Hofmann et al., Genome-wide analysis implicates micrornas and their target genes in the development of bipolar disorder Table of contents Supplementary Figure 1: Regional

More information

Genetic Testing and Analysis. (858) MRN: Specimen: Saliva Received: 07/26/2016 GENETIC ANALYSIS REPORT

Genetic Testing and Analysis. (858) MRN: Specimen: Saliva Received: 07/26/2016 GENETIC ANALYSIS REPORT GBinsight Sample Name: GB4411 Race: Gender: Female Reason for Testing: Type 2 diabetes, early onset MRN: 0123456789 Specimen: Saliva Received: 07/26/2016 Test ID: 113-1487118782-4 Test: Type 2 Diabetes

More information

MSI positive MSI negative

MSI positive MSI negative Pritchard et al. 2014 Supplementary Figure 1 MSI positive MSI negative Hypermutated Median: 673 Average: 659.2 Non-Hypermutated Median: 37.5 Average: 43.6 Supplementary Figure 1: Somatic Mutation Burden

More information

Genomic approach for drug target discovery and validation

Genomic approach for drug target discovery and validation Genomic approach for drug target discovery and validation Hong-Hee Won, Ph.D. SAIHST, SKKU wonhh@skku.edu Well-known example of genetic findings triggering drug development Genetics Mendelian randomisation

More information

DOES THE BRCAX GENE EXIST? FUTURE OUTLOOK

DOES THE BRCAX GENE EXIST? FUTURE OUTLOOK CHAPTER 6 DOES THE BRCAX GENE EXIST? FUTURE OUTLOOK Genetic research aimed at the identification of new breast cancer susceptibility genes is at an interesting crossroad. On the one hand, the existence

More information

Home Brewed Personalized Genomics

Home Brewed Personalized Genomics Home Brewed Personalized Genomics The Quest for Meaningful Analysis Results of a 23andMe Exome Pilot Trio of Myself, Wife, and Son February 22, 2013 Gabe Rudy, Vice President of Product Development Exome

More information

Supplemental Table 1. The list of variants with their respective scores for each variant classifier Gene DNA Protein Align-GVGD Polyphen-2 CADD MAPP

Supplemental Table 1. The list of variants with their respective scores for each variant classifier Gene DNA Protein Align-GVGD Polyphen-2 CADD MAPP Supplemental Table 1. The list of variants with their respective scores for each variant classifier Gene DNA Protein Align-GVGD Polyphen-2 CADD MAPP Frequency Domain Mammals a 3 S/P b Mammals a 3 S/P b

More information

CITATION FILE CONTENT/FORMAT

CITATION FILE CONTENT/FORMAT CITATION For any resultant publications using please cite: Matthew A. Field, Vicky Cho, T. Daniel Andrews, and Chris C. Goodnow (2015). "Reliably detecting clinically important variants requires both combined

More information

Using the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep

Using the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep Using the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep Tom Walsh, PhD Division of Medical Genetics University of Washington Next generation sequencing Sanger sequencing gold

More information

Rare Variant Burden Tests. Biostatistics 666

Rare Variant Burden Tests. Biostatistics 666 Rare Variant Burden Tests Biostatistics 666 Last Lecture Analysis of Short Read Sequence Data Low pass sequencing approaches Modeling haplotype sharing between individuals allows accurate variant calls

More information

p.arg119gly p.arg119his p.ala179thr c.540+1g>a c.617_633+6del Prediction basis structure

p.arg119gly p.arg119his p.ala179thr c.540+1g>a c.617_633+6del Prediction basis structure a Missense ATG p.arg119gly p.arg119his p.ala179thr p.ala189val p.gly206trp p.gly206arg p.arg251his p.ala257thr TGA 5 UTR 1 2 3 4 5 6 7 3 UTR Splice Site, Frameshift b Mutation p.gly206trp p.gly4fsx50 c.138+1g>a

More information

Variant Annotation and Functional Prediction

Variant Annotation and Functional Prediction Variant Annotation and Functional Prediction Copyrighted 2018 Isabelle Schrauwen and Suzanne M. Leal This exercise touches on several functionalities of the program ANNOVAR to annotate and interpret candidate

More information

Identification of heritable genetic risk factors for bladder cancer through genome-wide association studies (GWAS)

Identification of heritable genetic risk factors for bladder cancer through genome-wide association studies (GWAS) BCAN 2014 August 9, 2014 Identification of heritable genetic risk factors for bladder cancer through genome-wide association studies (GWAS) Ludmila Prokunina-Olsson, PhD Investigator Laboratory of Translational

More information

SUPPLEMENTARY INFORMATION. Intron retention is a widespread mechanism of tumor suppressor inactivation.

SUPPLEMENTARY INFORMATION. Intron retention is a widespread mechanism of tumor suppressor inactivation. SUPPLEMENTARY INFORMATION Intron retention is a widespread mechanism of tumor suppressor inactivation. Hyunchul Jung 1,2,3, Donghoon Lee 1,4, Jongkeun Lee 1,5, Donghyun Park 2,6, Yeon Jeong Kim 2,6, Woong-Yang

More information

Supplementary information for: A functional variation in BRAP confers risk of myocardial infarction in Asian populations

Supplementary information for: A functional variation in BRAP confers risk of myocardial infarction in Asian populations Supplementary information for: A functional variation in BRAP confers risk of myocardial infarction in Asian populations Kouichi Ozaki 1, Hiroshi Sato 2, Katsumi Inoue 3, Tatsuhiko Tsunoda 4, Yasuhiko

More information

Nature Genetics: doi: /ng Supplementary Figure 1. Alternative splicing events in the 5K panel.

Nature Genetics: doi: /ng Supplementary Figure 1. Alternative splicing events in the 5K panel. Supplementary Figure 1 Alternative splicing events in the 5K panel. The majority of cryptic splicing occurred by creation of an AG or GT (Type I). While some other mutations increased the usage of a nearby

More information

Variant Classification. Author: Mike Thiesen, Golden Helix, Inc.

Variant Classification. Author: Mike Thiesen, Golden Helix, Inc. Variant Classification Author: Mike Thiesen, Golden Helix, Inc. Overview Sequencing pipelines are able to identify rare variants not found in catalogs such as dbsnp. As a result, variants in these datasets

More information

Title: Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A

Title: Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A 1 Title Page Title: Candidate Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis. Authors: Siew Lian Leong 1,2, Nathorn Chaiyakunapruk 1,3,4,5, Shaun Wen

More information

Reporting TP53 gene analysis results in CLL

Reporting TP53 gene analysis results in CLL Reporting TP53 gene analysis results in CLL Mutations in TP53 - From discovery to clinical practice in CLL Discovery Validation Clinical practice Variant diversity *Leroy at al, Cancer Research Review

More information

Table S2. Baseline characteristics of the Rotterdam Study for interaction analysis

Table S2. Baseline characteristics of the Rotterdam Study for interaction analysis Supplementary data Table S1. List of the primers for the cloning of precursor mir-4707 Table S2. Baseline characteristics of the Rotterdam Study for interaction analysis Table S3. List of the primers for

More information

한국지질동맥경화학회, 부산 BEXCO, 2010 년 4 월 16 일

한국지질동맥경화학회, 부산 BEXCO, 2010 년 4 월 16 일 한국지질동맥경화학회, 부산 BEXCO, 2010 년 4 월 16 일 Dietary intake of folate, vitamin B2, vitamin B6, vitamin B12, genetic polymorphism of related enzymes, and risk of breast cancer: a case-control study in Korea KIM

More information

IPA Advanced Training Course

IPA Advanced Training Course IPA Advanced Training Course October 2013 Academia sinica Gene (Kuan Wen Chen) IPA Certified Analyst Agenda I. Data Upload and How to Run a Core Analysis II. Functional Interpretation in IPA Hands-on Exercises

More information

Somatic intronic microsatellite loci differentiate glioblastoma from lower-grade gliomas

Somatic intronic microsatellite loci differentiate glioblastoma from lower-grade gliomas 1 Somatic intronic microsatellite loci differentiate glioblastoma from lower-grade gliomas 2 3 FIGURE S1: Sensitivity & Specificity receiver operator characteristics (ROC) of Signature Cancer-Associated

More information

Supplementary Table 1. Annotated candidate SNV and indels in melanoma tumors. Patient C1 Patient C2 Patient C3 Patient C4 Patient C5 Patient C6 Patient C7 Patient C10 Chr Position Reference Allele Sample

More information

Shashikant Kulkarni, M.S (Medicine)., Ph.D., FACMG Associate Professor of Pathology & Immunology Associate Professor of Pediatrics and Genetics

Shashikant Kulkarni, M.S (Medicine)., Ph.D., FACMG Associate Professor of Pathology & Immunology Associate Professor of Pediatrics and Genetics Shashikant Kulkarni, M.S (Medicine)., Ph.D., FACMG Associate Professor of Pathology & Immunology Associate Professor of Pediatrics and Genetics Director of Cytogenomics and Molecular Pathology Evidence-based

More information

Effects of Obesity Related Genetic Variations on Visceral and Subcutaneous Fat Distribution in a Chinese Population

Effects of Obesity Related Genetic Variations on Visceral and Subcutaneous Fat Distribution in a Chinese Population Effects of Obesity Related Genetic Variations on Visceral and Subcutaneous Fat Distribution in a Chinese Population Tao Wang #, Xiaojing Ma #, Danfeng Peng, Rong Zhang, Xue Sun, Miao Chen, Jing Yan, Shiyun

More information

Supplementary Methods

Supplementary Methods Supplementary Methods Short Read Preprocessing Reads are preprocessed differently according to how they will be used: detection of the variant in the tumor, discovery of an artifact in the normal or for

More information

Supplemental Table 1. List of genes and mature shrna sequences identified from the shrna screen in BRCA2-mutant PEO1 cells.

Supplemental Table 1. List of genes and mature shrna sequences identified from the shrna screen in BRCA2-mutant PEO1 cells. Guillemette_Supplemental Table 1 Gene Mature Sequence Gene Mature Sequence ATTCATAGGATGTCAGCAG LOC157193 TATGCGTAAGTAATAAATTGCT TTAGTTCTGTCTTGGAGG LOC152225 CGCATATATGTTCTGACTT ALDH2 CACTTCAGTGTATGCCT

More information

Nutritional Epidemiology in the Genomic Age. Saroja Voruganti, PhD Assistant Professor Department of Nutrition and UNC Nutrition Research Institute

Nutritional Epidemiology in the Genomic Age. Saroja Voruganti, PhD Assistant Professor Department of Nutrition and UNC Nutrition Research Institute Nutritional Epidemiology in the Genomic Age Saroja Voruganti, PhD Assistant Professor Department of Nutrition and UNC Nutrition Research Institute Learning objectives Types of genetic association approaches

More information

Supplementary Information. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small

Supplementary Information. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small Sato T, et al. Supplementary Information PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer Teruyuki Sato 1,2, Atsushi Kaneda 1,3,4 *, Shingo Tsuji

More information

Next generation histopathological diagnosis for precision medicine in solid cancers

Next generation histopathological diagnosis for precision medicine in solid cancers Next generation histopathological diagnosis for precision medicine in solid cancers from genomics to clinical application Aldo Scarpa ARC-NET Applied Research on Cancer Department of Pathology and Diagnostics

More information

LMM / emerge III Network Reference Sequences October 2016 LMM / emerge III Network Consensus Actionable Gene List *ACMG56 gene

LMM / emerge III Network Reference Sequences October 2016 LMM / emerge III Network Consensus Actionable Gene List *ACMG56 gene LMM / emerge III Network Consensus Actionable Gene List *ACMG56 gene ACTA2* Exon 02-09 NM_001613.2 DSG2* Exon 01-15 NM_001943.3 ACTC1* Exon 01-06 NM_005159.4 DSP* Exon 01-24 NM_004415.2 APC* Exon 01-15

More information

Genome Summary. Sequencing Coverage: Variation Counts: Known Phenotype Summary: 131 disease or trait variations are found in this genome

Genome Summary. Sequencing Coverage: Variation Counts: Known Phenotype Summary: 131 disease or trait variations are found in this genome Report Date: August 2, 215 Software Annotation Version: 8 Genome Summary Name: Greg Mendel Genome ID: genome_greg_mendel_dad Sequencing Provider: 23andMe Sequencing Type: Genotyping SNP Array Sequencing

More information

A Rare View Of Coding Mutations And Plasma Lipid Levels

A Rare View Of Coding Mutations And Plasma Lipid Levels Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine January 2014 A Rare View Of Coding Mutations And Plasma Lipid Levels

More information

Supplementary Figure 1: Classification scheme for non-synonymous and nonsense germline MC1R variants. The common variants with previously established

Supplementary Figure 1: Classification scheme for non-synonymous and nonsense germline MC1R variants. The common variants with previously established Supplementary Figure 1: Classification scheme for nonsynonymous and nonsense germline MC1R variants. The common variants with previously established classifications 1 3 are shown. The effect of novel missense

More information

Ct=28.4 WAT 92.6% Hepatic CE (mg/g) P=3.6x10-08 Plasma Cholesterol (mg/dl)

Ct=28.4 WAT 92.6% Hepatic CE (mg/g) P=3.6x10-08 Plasma Cholesterol (mg/dl) a Control AAV mtm6sf-shrna8 Ct=4.3 Ct=8.4 Ct=8.8 Ct=8.9 Ct=.8 Ct=.5 Relative TM6SF mrna Level P=.5 X -5 b.5 Liver WAT Small intestine Relative TM6SF mrna Level..5 9.6% Control AAV mtm6sf-shrna mtm6sf-shrna6

More information

Germline Testing for Hereditary Cancer with Multigene Panel

Germline Testing for Hereditary Cancer with Multigene Panel Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with

More information

Genotypes of patients with factor XI deficiency Mutation Location Domain Type Genotype Origin Activity U/dL

Genotypes of patients with factor XI deficiency Mutation Location Domain Type Genotype Origin Activity U/dL Genotypes of patients with factor XI deficiency Mutation Location Domain Type Genotype Origin Activity U/dL Antigen U/dL Expression comments Reference nt-1296g>a Promoter Promoter Regulatory Comp het Nigeria

More information

DYSREGULATION OF WT1 (-KTS) IS ASSOCIATED WITH THE KIDNEY-SPECIFIC EFFECTS OF THE LMX1B R246Q MUTATION

DYSREGULATION OF WT1 (-KTS) IS ASSOCIATED WITH THE KIDNEY-SPECIFIC EFFECTS OF THE LMX1B R246Q MUTATION DYSREGULATION OF WT1 (-KTS) IS ASSOCIATED WITH THE KIDNEY-SPECIFIC EFFECTS OF THE LMX1B R246Q MUTATION Gentzon Hall 1,2#, Brandon Lane 1,3#, Megan Chryst-Ladd 1,3, Guanghong Wu 1,3, Jen-Jar Lin 4, XueJun

More information

EIGEN: A SPECTRAL APPROACH TO THE INTEGRATION OF FUNCTIONAL GENOMICS ANNOTATIONS FOR BOTH CODING AND NONCODING SEQUENCE VARIANTS

EIGEN: A SPECTRAL APPROACH TO THE INTEGRATION OF FUNCTIONAL GENOMICS ANNOTATIONS FOR BOTH CODING AND NONCODING SEQUENCE VARIANTS EIGEN: A SPECTRAL APPROACH TO THE INTEGRATION OF FUNCTIONAL GENOMICS ANNOTATIONS FOR BOTH CODING AND NONCODING SEQUENCE VARIANTS IULIANA IONITA-LAZA 1,7,, KENNETH MCCALLUM 1,7, BIN XU 2, JOSEPH BUXBAUM

More information

Supplementary Figures. Supplementary Figure 1. Dinucleotide variant proportions. These are described and quantitated. for each lesion type.

Supplementary Figures. Supplementary Figure 1. Dinucleotide variant proportions. These are described and quantitated. for each lesion type. Supplementary Figures Supplementary Figure 1. Dinucleotide variant proportions. These are described and quantitated for each lesion type. a b Supplementary Figure 2. Non-negative matrix factorization-derived

More information

Supplementary Information to

Supplementary Information to Supplementary Information to Exome sequencing to identify de novo mutations in sporadic ALS trios Alessandra Chesi 1,11, Brett T. Staahl 2, Ana Jovicic 1, Julien Couthouis 1, Maria Fasolino 3, Alya R.

More information

Supplemental Tables and Figures

Supplemental Tables and Figures Supplemental Tables and Figures Post-zygotic de novo changes in glutamate and dopamine pathways may explain discordance of monozygotic twins for schizophrenia Castellani, CA., Melka, MG., Gui, JL., Gallo,

More information

Nature Genetics: doi: /ng Supplementary Figure 1. Somatic coding mutations identified by WES/WGS for 83 ATL cases.

Nature Genetics: doi: /ng Supplementary Figure 1. Somatic coding mutations identified by WES/WGS for 83 ATL cases. Supplementary Figure 1 Somatic coding mutations identified by WES/WGS for 83 ATL cases. (a) The percentage of targeted bases covered by at least 2, 10, 20 and 30 sequencing reads (top) and average read

More information

Supplementary Figure 1: Attenuation of association signals after conditioning for the lead SNP. a) attenuation of association signal at the 9p22.

Supplementary Figure 1: Attenuation of association signals after conditioning for the lead SNP. a) attenuation of association signal at the 9p22. Supplementary Figure 1: Attenuation of association signals after conditioning for the lead SNP. a) attenuation of association signal at the 9p22.32 PCOS locus after conditioning for the lead SNP rs10993397;

More information

Transient cold shock enhances zinc-finger nuclease mediated gene disruption

Transient cold shock enhances zinc-finger nuclease mediated gene disruption nature methods Transient cold shock enhances zincfinger nuclease mediated gene disruption Yannick Doyon, Vivian M Choi, Danny Xia, Thuy D Vo, Philip D Gregory & Michael C Holmes Supplementary figures and

More information

Whole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute

Whole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Whole Genome and Transcriptome Analysis of Anaplastic Meningioma Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Outline Anaplastic meningioma compared to other cancers Whole genomes

More information

Whole exome sequencing. Information for Patients and Families

Whole exome sequencing. Information for Patients and Families Whole exome sequencing Information for Patients and Families The medical genetics laboratories Your health care provider has advised you to have genetic testing on your DNA or your child s DNA. The specific

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Ahlqvist E, Storm P, Käräjämäki A, et al. Novel

More information

Prevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D.

Prevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D. Prevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D. Hereditary Cancer Center, Peking University Cancer Hospital 1 Breast cancer

More information

SUPPLEMENTARY INFORMATION. Rare independent mutations in renal salt handling genes contribute to blood pressure variation

SUPPLEMENTARY INFORMATION. Rare independent mutations in renal salt handling genes contribute to blood pressure variation SUPPLEMENTARY INFORMATION Rare independent mutations in renal salt handling genes contribute to blood pressure variation Weizhen Ji, Jia Nee Foo, Brian J. O Roak, Hongyu Zhao, Martin G. Larson, David B.

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION SUPPLEMENTARY INFORMATION Systematic investigation of cancer-associated somatic point mutations in SNP databases HyunChul Jung 1,2, Thomas Bleazard 3, Jongkeun Lee 1 and Dongwan Hong 1 1. Cancer Genomics

More information

2) Cases and controls were genotyped on different platforms. The comparability of the platforms should be discussed.

2) Cases and controls were genotyped on different platforms. The comparability of the platforms should be discussed. Reviewers' Comments: Reviewer #1 (Remarks to the Author) The manuscript titled 'Association of variations in HLA-class II and other loci with susceptibility to lung adenocarcinoma with EGFR mutation' evaluated

More information

How will new biomarkers change bladder cancer management? John Kelly Professor of Uro-Oncology UCL

How will new biomarkers change bladder cancer management? John Kelly Professor of Uro-Oncology UCL How will new biomarkers change bladder cancer management? John Kelly Professor of Uro-Oncology UCL What do we mean by biomarker? a measurable indicator of the severity or presence of some disease state.

More information

STATISTICAL METHODS IN BIOLOGY

STATISTICAL METHODS IN BIOLOGY STATISTICAL METHODS IN BIOLOGY JOANNA SZYDA MAGDALENA FRĄSZCZAK INTRODUCTION 1. Statistical methods in biology??? 2. The Biostatistic Group current projects 3. Course contents 4. Contact 5. Literature

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Lyall DM, Celis-Morales C, Ward J, et al. Association of body mass index with cardiometabolic disease in the UK Biobank: a mendelian randomization study. JAMA Cardiol. Published

More information

Nature Genetics: doi: /ng Supplementary Figure 1. Country distribution of GME samples and designation of geographical subregions.

Nature Genetics: doi: /ng Supplementary Figure 1. Country distribution of GME samples and designation of geographical subregions. Supplementary Figure 1 Country distribution of GME samples and designation of geographical subregions. GME samples collected across 20 countries and territories from the GME. Pie size corresponds to the

More information

Editorial Type 2 Diabetes and More Gene Panel: A Predictive Genomics Approach for a Polygenic Disease

Editorial Type 2 Diabetes and More Gene Panel: A Predictive Genomics Approach for a Polygenic Disease Cronicon OPEN ACCESS EC DIABETES AND METABOLIC RESEARCH Editorial Type 2 Diabetes and More Gene Panel: A Predictive Genomics Approach for a Polygenic Disease Amr TM Saeb* University Diabetes Center, College

More information

Nature Structural & Molecular Biology: doi: /nsmb Supplementary Figure 1

Nature Structural & Molecular Biology: doi: /nsmb Supplementary Figure 1 Supplementary Figure 1 Frequency of alternative-cassette-exon engagement with the ribosome is consistent across data from multiple human cell types and from mouse stem cells. Box plots showing AS frequency

More information

Supplemental Information For: The genetics of splicing in neuroblastoma

Supplemental Information For: The genetics of splicing in neuroblastoma Supplemental Information For: The genetics of splicing in neuroblastoma Justin Chen, Christopher S. Hackett, Shile Zhang, Young K. Song, Robert J.A. Bell, Annette M. Molinaro, David A. Quigley, Allan Balmain,

More information

Influence of genetic ancestry and socioeconomic status on type 2 diabetes in the diverse Colombian populations of Chocó and Antioquia

Influence of genetic ancestry and socioeconomic status on type 2 diabetes in the diverse Colombian populations of Chocó and Antioquia Supplementary Information For: Influence of genetic ancestry and socioeconomic status on type 2 diabetes in the diverse Colombian populations of Chocó and Antioquia Aroon T. Chande 1,2,3, Jessica Rowell

More information

A rare variant in MYH6 confers high risk of sick sinus syndrome. Hilma Hólm ESC Congress 2011 Paris, France

A rare variant in MYH6 confers high risk of sick sinus syndrome. Hilma Hólm ESC Congress 2011 Paris, France A rare variant in MYH6 confers high risk of sick sinus syndrome Hilma Hólm ESC Congress 2011 Paris, France Disclosures I am an employee of decode genetics, Reykjavik, Iceland. Sick sinus syndrome SSS is

More information

PALB2 c g>c is. VARIANT OF UNCERTAIN SIGNIFICANCE (VUS) CGI s summary of the available evidence is in Appendices A-C.

PALB2 c g>c is. VARIANT OF UNCERTAIN SIGNIFICANCE (VUS) CGI s summary of the available evidence is in Appendices A-C. Consultation sponsor (may not be the patient): First LastName [Patient identity withheld] Date received by CGI: 2 Sept 2017 Variant Fact Checker Report ID: 0000001.5 Date Variant Fact Checker issued: 12

More information

MEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)

MEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Ordering Information Acceptable specimen types: Fresh blood sample (3-6 ml EDTA; no time limitations associated with receipt)

More information

Fluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS

Fluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS APPLICATION NOTE Fluxion Biosciences and Swift Biosciences OVERVIEW This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor

More information

genomics for systems biology / ISB2020 RNA sequencing (RNA-seq)

genomics for systems biology / ISB2020 RNA sequencing (RNA-seq) RNA sequencing (RNA-seq) Module Outline MO 13-Mar-2017 RNA sequencing: Introduction 1 WE 15-Mar-2017 RNA sequencing: Introduction 2 MO 20-Mar-2017 Paper: PMID 25954002: Human genomics. The human transcriptome

More information

A suppressor locus for MODY3-diabetes

A suppressor locus for MODY3-diabetes A suppressor locus for MODY3-diabetes Miguel A. Garcia-Gonzalez 1,2, Claire Carette 1,3, Alessia Bagattin 1, Magali Chiral 1, Munevver Parla Makinistoglu 1, Serge Garbay 1, Géraldine Prévost 4, Cécile

More information

Nature Genetics: doi: /ng Supplementary Figure 1

Nature Genetics: doi: /ng Supplementary Figure 1 Supplementary Figure 1 LD (r 2 ) between the A3AB deletion and all markers in a 400-kb APOBEC3 region in 1000 Genomes Project populations. Populations: CEU, individuals of European ancestry from Utah,

More information

Supplementary Figure 1. A - MSH6 p.val282thrfs*10: Endome. Endome. Colon

Supplementary Figure 1. A - MSH6 p.val282thrfs*10: Endome. Endome. Colon Supplementary Figure 1 - MSH6 p.val282hrfs*10: 1780 1785 C C C C C 1 B - MSH6 p.phe1088leufs*5: 1820 1810 Rectal Rectal Gastric C C C C C C Rectal C 2 C - MSH6 p.rg1172lysfs*5: 1745 1740 Ovarian 3 D -

More information

Next generation sequencing of BRCA1 and BRCA2 in breast cancer patients and control subjects

Next generation sequencing of BRCA1 and BRCA2 in breast cancer patients and control subjects MOLECULAR AND CLINICAL ONCOLOGY 2: 435-439, 2014 Next generation sequencing of BRCA1 and BRCA2 in breast cancer patients and control subjects LUBOMIR BALABANSKI 1*, GEORGI ANTOV 2*, IVANKA DIMOVA 3, SAMUIL

More information

Supplemental Table 1. Components of MDS and AHEI

Supplemental Table 1. Components of MDS and AHEI Supplemental Table 1. Components of MDS and AHEI MDS AHEI Vegetable Fruit SSB & fruit juice Nut Legume Whole grain Fish Red meat MUFA/SAT ratio EPA & DHA PUFA Trans-fat Alcohol Sodium MDS: Mediterranean-style

More information

Welcome to the Genetic Code: An Overview of Basic Genetics. October 24, :00pm 3:00pm

Welcome to the Genetic Code: An Overview of Basic Genetics. October 24, :00pm 3:00pm Welcome to the Genetic Code: An Overview of Basic Genetics October 24, 2016 12:00pm 3:00pm Course Schedule 12:00 pm 2:00 pm Principles of Mendelian Genetics Introduction to Genetics of Complex Disease

More information

The lymphoma-associated NPM-ALK oncogene elicits a p16ink4a/prb-dependent tumor-suppressive pathway. Blood Jun 16;117(24):

The lymphoma-associated NPM-ALK oncogene elicits a p16ink4a/prb-dependent tumor-suppressive pathway. Blood Jun 16;117(24): DNA Sequencing Publications Standard Sequencing 1 Carro MS et al. DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle. 2006 Jun;5(11) 2 Lassandro L et al. The DNA sequence

More information

RNA SEQUENCING AND DATA ANALYSIS

RNA SEQUENCING AND DATA ANALYSIS RNA SEQUENCING AND DATA ANALYSIS Download slides and package http://odin.mdacc.tmc.edu/~rverhaak/package.zip http://odin.mdacc.tmc.edu/~rverhaak/rna-seqlecture.zip Overview Introduction into the topic

More information

A total of 2,822 Mexican dyslipidemic cases and controls were recruited at INCMNSZ in

A total of 2,822 Mexican dyslipidemic cases and controls were recruited at INCMNSZ in Supplemental Material The N342S MYLIP polymorphism is associated with high total cholesterol and increased LDL-receptor degradation in humans by Daphna Weissglas-Volkov et al. Supplementary Methods Mexican

More information

Nature Genetics: doi: /ng Supplementary Figure 1. TCGA data set on HNSCCs reanalyzed in this study.

Nature Genetics: doi: /ng Supplementary Figure 1. TCGA data set on HNSCCs reanalyzed in this study. Supplementary Figure 1 TCGA data set on HNSCCs reanalyzed in this study. Summary of the TCGA dataset on HNSCCs re-analyzed in this study and the respective numbers of samples available within each. Supplementary

More information

ACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics

ACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics ACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics Precision Genomics for Immuno-Oncology Personalis, Inc. ACE ImmunoID When one biomarker doesn t tell the whole

More information

Epigenetics. Jenny van Dongen Vrije Universiteit (VU) Amsterdam Boulder, Friday march 10, 2017

Epigenetics. Jenny van Dongen Vrije Universiteit (VU) Amsterdam Boulder, Friday march 10, 2017 Epigenetics Jenny van Dongen Vrije Universiteit (VU) Amsterdam j.van.dongen@vu.nl Boulder, Friday march 10, 2017 Epigenetics Epigenetics= The study of molecular mechanisms that influence the activity of

More information

RNA SEQUENCING AND DATA ANALYSIS

RNA SEQUENCING AND DATA ANALYSIS RNA SEQUENCING AND DATA ANALYSIS Length of mrna transcripts in the human genome 5,000 5,000 4,000 3,000 2,000 4,000 1,000 0 0 200 400 600 800 3,000 2,000 1,000 0 0 2,000 4,000 6,000 8,000 10,000 Length

More information

Molecular Diagnosis of Genetic Diseases: From 1 Gene to 1000s

Molecular Diagnosis of Genetic Diseases: From 1 Gene to 1000s ROMA, 23 GIUGNO 2011 Molecular Diagnosis of Genetic Diseases: From 1 Gene to 1000s USSD Lab Genetica Medica Ospedali Riuniti Bergamo The problem What does the clinician/patient want to know?? Diagnosis,

More information